Maven Renovar VCT PLC

Quarterly Factsheet

October 2025

INVESTMENT OBJECTIVE

To generate tax free capital gains and regular dividend income for its Shareholders while complying with the requirements of the rules and regulations applicable to VCTs.

INVESTMENT POLICY

To hold a diversified portfolio across a broad range of sectors to mitigate risk. The VCT makes Qualifying Investments primarily in AIM-traded companies, and Non-Qualifying Investments as allowed by the VCT legislation, and manages its portfolio to comply with the requirements of the rules and regulations applicable to VCTs.

KEY DATA / 31 OCTOBER 2025		
Туре	AIM Focused	
Launched	January 2001	
Maven appointment	May 2025	
No. of holdings	61	
Dividend target	6% of NAV per Share ¹	
Buyback policy	5% discount to NAV per Share ²	
Webpage	mavencp.com/renovarvct	

MAVEN

FINANCIAL HIGHLIGHTS

£95.85m

Net asset value (NAV)

2.50p + 2.50p

Interim & special dividend per Share (14 November 2025) 66.91p

NAV per Share

17.42%³

Annual Yield (FY25)

-0.49%


NAV total return for Quarter


214.25p

NAV total return per Share

NAV TOTAL RETURN


PORTFOLIO COMPOSITION (% of NAV)






VCT QUALIFYING INVESTMENTS – 31 OCTOBER 2025

SECTOR ANALYSIS (BY VALUE)⁴



Software & technology is widely diversified by end market, including data analytics, enterprise software, electronics and fintech.

AGE PROFILE OF INVESTMENTS (BY VALUE)4



Age of investment is determined by the date of the VCT's first investment in each company.

TOP TEN HOLDINGS	% of NAV
WS Amati Smaller Companies Fund	10.0
2 Degrees (Trading as Manufacture 2030)	6.6
Craneware	5.0
The Property Franchise Group	4.5
Diaceutics	3.4
Chorus Intelligence	3.0
GB Group	2.8
SRT Marine	2.5
Aurrigo	2.4
Windar Photonics	2.4

CORPORATE AND CONTACT INFORMATION

Maven Capital Partners UK LLP 41 306 7400 / (Authorised and regulated by the FCA)

The City Partnership (UK) Limited 01484 240910 / registrars@city.uk.com

TIDM: MRV

ISIN: GB00B641BB82

Company Number: 04138683 Costs⁵: Cannod et 2 Capped at 3.5% of NAV. Management Fee of 1.95%

waived until April 2027.

PERFORMANCE COMMENTARY

Global equities continued to climb during the guarter. Trade tensions subsided as the US signed further trade deals and held constructive talks with China, though the UK market underperformed due to stubbornly high inflation and concerns surrounding the upcoming Budget. The AIM market saw a 1.87% gain in the period but that included a large rise for the mining sector: most industry groups were in fact lower. The VCT's NAV per Share declined by 0.49% to 66.91p.

Aurrigo declined 27%, reversing much of its gain from the first half of the year. In August, the company warned that tariffs were impacting its Automotive division, and it had seen delays in its Autonomous airport vehicle programmes, causing a revenue shortfall. Subsequently, the company completed a large £13.8m fundraise at 45p per share including the introduction of a new lead investor. While this dilutes the VCT's ownership percentage position, it strengthens Aurrigo's longer term financial position.

More positively, the largest gain came from Diaceutics which rose 22%, reporting strong growth in its first half results and continued demand for its pharma commercialisation solutions. Xeros Technology rallied after announcing a product launch agreement with a leading washing machine brand. Frontier Developments was buoyed by its share buyback programme and rallied through the launch of a major franchise video game: the new release has been well received in contrast to disappointing new games in recent years. SRT Marine was again strong as it continued to deliver its major marine intelligence contracts and reported record revenues for its full financial year.

As part of the stated strategy, Maven began the process of rationalising the portfolio, with partial sales of SRT Marine and The Property Franchise Group after their recent gains and exiting the holding in Sosander. In addition, smaller sales were completed in Fusion Antibodies, Xeros Technology, and Polarean Imaging, which is considering delisting.

OUTLOOK

The Board have declared interim and special dividends totalling 5.00p per Share, paid in November from the VCT's existing liquidity. As previously outlined in the 2025 Interim Report, the Manager intends to make further sales from the AIM portfolio and it is anticipated that the proceeds will be distributed to Shareholders through further dividends and potentially a tender offer on which the Board intends to consult Shareholders. We believe this strategy will protect value, return investors' capital efficiently, and offers an exit for Shareholders seeking to realise their investment in full.

At the same time, selective new investments will be completed under the existing investment policy, aiming to return the VCT to a steady growth path for Shareholders invested for the longer term.

Maven and the Board continue to be available to answer your queries and hear the views of Shareholders.